Smith & Nephew Reports Strong 2025 Results, Launches New 'RISE' Growth Strategy, and Completes Share Buyback
SNN sits 39% above its 52-week low of $23.91 on light trading volume (0.1× avg).
Summary
Smith & Nephew reported strong 2025 financial results, launched a new 3-year 'RISE' growth strategy with ambitious targets, completed a $500 million share buyback, and announced a significant acquisition, signaling a positive outlook.
Key Events · Earnings and Guidance · SNN
-
Strong 2025 Financial Performance
Reported revenue increased by 6.1% to $6,164 million, operating profit rose by 20.7% to $794 million, and free cash flow surged by 52.5% to $840 million. Basic EPS grew by 52.8% to 72.1 cents, and adjusted EPS (EPSA) increased by 21.0% to 102.0 cents.
-
Launches New 'RISE' Growth Strategy
The company completed its 12-Point Plan and introduced a new 'RISE' strategy for 2026-2028, targeting 6-7% organic revenue CAGR, 9-10% trading profit CAGR, over $1 billion in free cash flow, and 12-13% adjusted ROIC by 2028.
-
Completes $500M Share Buyback
Smith & Nephew completed a $500 million share buyback program in the second half of 2025, returning capital to shareholders while maintaining its leverage ratio.
-
Acquires Integrity Orthopaedics
In January 2026, the company acquired Integrity Orthopaedics for an initial cash payment of $225 million, with potential additional performance-based payments of up to $225 million over five years, enhancing its Sports Medicine portfolio.
Analysis · SNN · Industrial Applications And Services
Smith & Nephew PLC delivered robust financial performance in 2025, exceeding prior year targets across key metrics including revenue, operating profit, EPS, and free cash flow. The company successfully completed its 12-Point Plan and introduced a new 'RISE' strategy with ambitious 2028 financial targets, signaling a strong growth outlook. Strategic capital allocation was evident through a significant share buyback and a notable acquisition, reinforcing the company's market position and commitment to shareholder value. Proposed changes to executive remuneration, aimed at aligning with competitive MedTech market practices, will be a key focus for shareholders.
At the time of this filing, SNN was trading at $33.34 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $14B. The 52-week trading range was $23.91 to $38.79. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.